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Abstract
Although numerous positron emission tomography (PET)
studies with 18F-ﬂuoro-deoxyglucose (FDG) have reported
quantitative results on cerebral glucose kinetics and con-
sumption, there is a large variation between the absolute
values found in the literature. One of the underlying causes is
the inconsistent use of the lumped constants (LCs), the
derivation of which is often based on multiple assumptions that
render absolute numbers imprecise and errors hard to
quantify. We combined a kinetic FDG-PET study with mag-
netic resonance spectroscopic imaging (MRSI) of glucose
dynamics in Sprague–Dawley rats to obtain a more compre-
hensive view of brain glucose kinetics and determine a reliable
value for the LC under isoﬂurane anaesthesia. Maps of
Tmax/CMRglc derived from MRSI data and Tmax determined
from PET kinetic modelling allowed to obtain an LC-indepen-
dent CMRglc. The LC was estimated to range from 0.33  0.07
in retrosplenial cortex to 0.44  0.05 in hippocampus, yielding
CMRglc between 62  14 and 54  11 lmol/min/100 g,
respectively. These newly determined LCs for four distinct
areas in the rat brain under isoﬂurane anaesthesia provide
means of comparing the growing amount of FDG-PET data
available from translational studies.
Keywords: CMRglc, glucose transport, isoﬂurane, lumped
constant, magnetic resonance spectroscopic imaging, positron
emission tomography.
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Cerebral glucose metabolism is linked to neurotransmitter
cycling (Sibson et al. 1998) and therefore indicative of
neuronal activity. It is also known to be altered in various
pathologies, such as hypoxia and ischaemia, Alzheimer’s and
Parkinson’s diseases (Hellwig et al. 2012; Scheef et al.
2012). As energy consumption in the brain is affected by
numerous factors, it is all the more desirable to measure it in
a fully quantitative fashion to allow for comparison across
studies performed under different conditions in different
laboratories.
Brain glucose consumption in vivo has been determined in
a non-invasive way mostly using 13C magnetic resonance
spectroscopy (MRS) with infusion of 13C-enriched glucose,
1H MRS upon glycaemia challenges and positron emission
tomography (PET) with the glucose analog 18F-ﬂuoro-
deoxyglucose (FDG). Notwithstanding its great merits,
particularly allowing to determine ﬂuxes through a large
number of metabolic reactions, 13C MRS faces limitations
regarding spatial resolution. Although 1H MRS has been
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mostly restricted to provide information on the ratio of
glucose transport over consumption, recent studies have been
designed to quantify both transport kinetics and the cerebral
metabolic rate of glucose (CMRglc) from the dynamic
measurement of brain glucose concentration upon plasma
glucose variation (Gruetter et al. 1996; Shestov et al. 2011;
Du et al. 2012; Duarte and Gruetter 2012a). PET with FDG
offers information on the mechanistic basis of CMRglc and is
a relatively uncomplicated method, leading to its widespread
employment. However, it is most often used in a semiquan-
titative manner, reporting standard uptake values rather than
calibrated kinetic modelling results (Liu et al. 2010; Mizuma
et al. 2010; Kreissl et al. 2011). This has been criticized in
the past (Keyes 1995) and is because of two principal issues.
The ﬁrst is the need for a measurement of the FDG
concentration in the blood (the so-called input function),
which in rodents is complicated by small blood volume.
There are commercially available tools for the real-time
measurement of the input function in rats (Weber et al. 2002)
and mice (Alf et al. 2013a). The second issue relates to the
need of the lumped constant (LC), which accounts for the
different afﬁnities of glucose versus its analog, in this case
FDG, to glucose transporters and hexokinase and their
volumes of distribution. This is particularly needed to derive
a value for the consumption of glucose from data describing
the uptake of its analog. A good discussion of why the LC is
difﬁcult to determine can be found in a perspective article by
Krohn et al. (2007). Most previous attempts to determine the
LC of FDG have been based on an indirect comparison to
14C-DG, for which the LC has been determined in the
seminal work in the ﬁeld (Sokoloff et al. 1977), and used
operational deﬁnitions drawing upon average values for
single rate constants from the literature (Tokugawa et al.
2007). The latest reported value for the LC in the awake rat
for FDG is 0.71  0.12 (Tokugawa et al. 2007). Although a
large number of FDG-PET studies in rats are performed
under isoﬂurane anaesthesia (e.g. Shimoji et al. 2004;
Backes et al. 2011), there is no consensus on the LC to be
used in this condition. Recent efforts to calculate LCs for
individual animals yielded qualitatively meaningful results
but failed to provide realistic values of CMRglc (Backes et al.
2011). Overall, there are substantial differences between
published results (Table 1) that prohibit comparison between
studies from different research groups and suggest a pseudo-
quantitative and somewhat arbitrary nature of CMRglc
measurements.
Hyder and Rothman (2012) have collected data on CMRglc
from rats mostly from 13C MRS studies that suggest a
minimum CMRglc of 10–20 lmol/min/100 g to be required
to maintain cell viability even at isoelectricity, i.e. in the
absence of electrical activity that can be reached with deep
pentobarbital anaesthesia (Crane et al. 1978; Sakabe et al.
1985). Although isoﬂurane has a suppressive effect on neural
activity, it has been used in stimulation studies (e.g. Barter
et al. 2005) and it has been demonstrated to only partially
reduce haemodynamic signals in rodents at conventionally
used doses (e.g. Takuwa et al. 2012). This suggests that one
should expect to ﬁnd a CMRglc somewhere above 20
lmol/min/100 g but below the consumption level of the
awake state that may be even above 100 lmol/min/100 g
(Moore et al. 2000; Tokugawa et al. 2007). Recent studies
in mice anaesthetized with isoﬂurane have reported values of
CMRglc as low as 13 and 18 lmol/min/100 g (Mizuma et al.
2010; Kreissl et al. 2011).
These discrepancies suggest the need for a new determi-
nation of the LC under isoﬂurane anaesthesia. We adopted an
entirely new approach to the issue by combining magnetic
resonance spectroscopic imaging (MRSI) and PET with FDG
to determine Tmax/CMRglc and Tmax respectively, in different
brain structures. With the standard two-tissue compartment
model, this allowed to estimate the actual LC under
isoﬂurane anaesthesia (LCisoﬂurane) without the need of using
Table 1 Values for CMRglc in the cortex (CTX), Hippocampus (HIP) or whole brain (WB) from rodents under isoﬂurane anaesthesia vary
considerably across studies. Except for the ﬁrst four rows, all results are from FDG-PET studies
Authors Species Brain region Tracer LC CMRglc (lmol/min/100 g)
Hansen et al. (1989) Rat CTX
HIP
14C-DG 0.483 (autoradiography) 54  2
66  2
Archer et al. (1990) Rat CTX
HIP
14C-DG 0.483 (autoradiography) 37  7 to 48  6
42  7 to 63  12
Duarte and Gruetter (2012a) Rat CTX+HIP None None (dynamic 1H MRS) 54  15
Du et al. (2012) Rat CTX None None (dynamic 1H MRS) 44  17
Shimoji et al. (2004) Rat CTX
WB
FDG 0.48 23.9  4.8
28.1  4.6
Backes et al. (2011) Rat WB FDG Derived from kinetics 20 (no SD reported)
Yu et al. (2009) Mouse CTX FDG 0.6 40.6  13.3
Mizuma et al. (2010) Mouse CTX FDG 0.625 13  4
Kreissl et al. (2011) Mouse WB FDG 1 18 (no SD reported)
Alf et al. (2012) Mouse WB FDG 0.6 61  11 to 75  24
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literature values on the LC for 14C-DG or single rate
constants. As there is an ongoing debate on whether it is
appropriate to include a rate constant k4 for dephosphory-
lation of FDG-6-phosphate, we derived results for both
modelling options, i.e. with and without k4 included in the
model. The combined information from PET and MRSI also
provided a more complete, quantitative description of
glucose kinetics in the rat brain. These ﬁndings contribute
to an improvement in the comparability of quantitative
results on brain glucose metabolism.
Materials and methods
All procedures used in the experiments described here were
according to the Swiss animal welfare legislation and approved by
the local ethics committee and performed by licensed investigators.
Male Sprague-Dawley rats for MRSI (253  23 g, n = 10) and
PET (304  9 g, n = 6) were purchased from Charles River in
France and Germany, respectively, and housed under identical
conditions: 12-h light–dark cycle, 20–22°C room temperature, 55–60%
humidity, with water and food (Kliba Nafag 3800 from Provimi Kliba)
provided ad libitum.
Animal preparation
Rats were anaesthetized using 1.5–2% isoﬂurane in 30% oxygen in
air, breathing autonomously at a rate of 60–75 breaths/min.
Polyethylene catheters were inserted into a femoral artery and vein.
In MRSI experiments, they were used to monitor blood gases, plasma
glucose (Gp), and lactate concentrations, and to infuse a 20% (w/v)
solution of D-glucose (Sigma-Aldrich, Basel, Switzerland), as
described previously (Duarte et al. 2009a). In PET experiments, the
catheterswere connected to form a closed shunt loopwith two- to three-
way valves in it, for infusion of FDGandGpmonitoring. The shunt was
guided through a coincidence counter (twilite, Swisstrace, Switzerland)
for the acquisition of real-time input functions with the respective tool
in PMODv3.3 software (PMODTechnologies Inc., Zurich, Switzerland),
as described previously (Weber et al. 2002; Alf et al. 2013a).
A peristaltic pump (Ismatec, Wertheim-Mondfeld, Germany) ensured
a constant ﬂow rate of 300 lL/min through the shunt.
PET imaging
FDG was administered as an infusion of 200 lL at constant speed
over 5 min with a syringe pump. The injected radioactive dose was
31–39 MBq. Gp was measured before, in the middle and after the
scan, i.e. with 30-min interval. For this purpose, plasma samples
were obtained by centrifugation of 40–50 lL whole blood samples
and Gp was measured with a glucose oxidase/reﬂectance system
(Vitros DT60 II; Ortho Clinical Diagnostics). Respiratory rate and
body temperature were continuously monitored and controlled as
described previously (Alf et al. 2013a).
List mode PET data acquisition was performed on a GE VISTA
eXplore PET/CT system (GE, Fairﬁeld, CT, USA) with 0.9-mm
resolution in full width at half maximum in the centre of ﬁeld of
view (Alf et al. 2013a,b). Data were collected over 60 min. Animals
were killed at the end of the experiment.
Images were reconstructed using a 3D FORE/2D OSEM algorithm
to a nominal voxel volume of 0.3875 9 0.3875 9 0.775 (axial) mm3
as described previously (Alf et al. 2013a,b). Time frames were
arranged insuchawaythat theshortest frames (10 s)coincidedwith the
fastest changes in blood concentration of radioactivity, i.e. the end of
the tracer infusion. The longest frames (4 min)were situated at the end
of the scan. In Fig. 2a, each data point of the time activity curve (TAC)
stems from one reconstructed time frame.
MR Spectroscopic imaging
Measurements of brain glucose concentrations were performed on a
DirectDrive spectrometer (Agilent Technologies, Palo Alto, CA,
USA) that was interfaced to an actively shielded 9.4 T magnet with a
31 cm horizontal bore (Magnex Scientiﬁc, Abingdon, UK) and with
a 12 cm i.d. actively shielded gradient set that allowed a maximum
gradient of 400 mT/m in 120 ls. A quadrature coil with two
12-mm-inner-diameter decoupled loops resonating at 400 MHz was
used for the radio-frequency transceiver.
We used a standard rectangular k-space acquisition scheme that
was accelerated by TR weighting with a 2D-Hamming ﬁlter and a
circular sampling window as described previously (K€uhn et al.
1996; Alf et al. 2012). Multislice T2-weighted (TR = 4 s,
TEeff = 52 ms, four scans) images were acquired with a fast spin-
echo method (Hennig 1988) for positioning of the volume of interest
(VOI) for subsequent MRSI scans. A coronally oriented VOI was
chosen with dimensions of 6 mm 9 9 mm with a thickness of
2.5 mm. SPECIAL (Spin Echo full Intensity Acquired Localized
spectroscopy; Mlynarik et al. 2008) combined with phase encoding
in two dimensions was used for the MRSI metabolite signal
acquisition with TE = 2.8 ms and a maximum TR of 2.5 s at the
centre of k-space. VAPOR water suppression interleaved with three
modules of outer volume saturation was employed. A 32 9 32
k-space data matrix was acquired, covering a ﬁeld of view of
24 mm 9 24 mm. Nominal voxel size was thus 1.4 lL. For the 4
averages acquired, metabolite acquisition time was 90 min and the
resulting Cramer-Rao lower bounds of glucose were < 30% also in
peripheral voxels, except for a few voxels in the corners and bottom
row. After the ﬁrst MRSI acquisition at baseline Gp, a water
reference map (acquisition time of 30 min) was recorded for
absolute quantiﬁcation, while glucose was infused to clamp its
plasma concentration to a higher level, as described previously
(Duarte and Gruetter 2012a). Once the new Gp was reached, a
waiting period of 90 min was observed to ensure for a steady state
of glucose transport in the brain, before a second MRSI acquisition
was started. The MRSI session took about 5 h altogether: 30 min
T2-weighted scan and shimming, 90 min metabolites, 30 min water
(during waiting period), 90 min metabolites. During the whole
MRSI session, body temperature, arterial blood pressure, heart rate,
and respiratory rate were continuously monitored with an animal
monitoring system (SA Instruments, NY, USA). Temperature was
maintained at 37.5°C with a warm water circulation system based on
the feedback obtained from a rectal temperature probe. Plasma
samples collected every 20 min as described above were used to
quantify concentrations of glucose and lactate, pH, PaO2 and PaCO2,
as detailed previously (Duarte and Gruetter 2012a).
Data analysis
PET images and input functions were calibrated to kBq/cm3 by
means of a phantom scan with known concentration that was
performed daily. With a rat brain template (Schiffer atlas as
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implemented in PMOD, Zurich, Switzerland), TACs were generated
from the brain structures present in the VOI used for MRSI
(Fig. 1a), i.e. somatosensory and retrosplenial cortex, hippocampus
and thalamus. TACs and input functions were used to perform
kinetic modelling with the two-tissue compartment model (Sokoloff
et al. 1977; Brooks 1982) in PMOD. In brief, the model comprises
plasma and tissue compartments and four rate constants that are used
to describe FDG metabolism: K1 (mL/min/cm
3) and k2 (min
1)
represent the rate constants for carrier-mediated transport of FDG
from plasma to tissue and back from tissue to plasma respectively;
k3 (min
1) represents the rate constant for FDG phosphorylation by
tissue hexokinase; k4 (min
1) represents the rate constant of FDG
dephosphorylation in tissue. In compartment models, K1 can be seen
as a rate constant corrected for the plasma/tissue volume ratio or as
the clearance of FDG from plasma (mL/min) per cm3 tissue. Kinetic
modelling was performed with two different variants of the two-
tissue compartment model: the ﬁrst variant included dephosphory-
lation of FDG-6-phosphate, k4; the other variant did not include
dephosphorylation in the model, i.e. irreversible phosphorylation of
FDG by hexokinases was assumed. A fractional blood volume of
4.2% was assumed according to synchrotron CT results (Adam
et al. 2003). Fitting was done with a Levenberg–Marquardt
algorithm.
The resulting single rate constants were used to compute the FDG
uptake constant (KFDG) and cerebral glucose metabolic rate
(CMRglc), for which an initial assumption of LC
assumed = 0.7 was
made, as suggested by the literature for awake rats (Tokugawa et al.
2007):
KFDG ¼ K1  k3k2 þ k3 ð1Þ
CMRglc ¼ KFDG  GpLCassumed ð2Þ
Glucose transport was calculated with
Tglc ¼ K1;glcGp ð3Þ
and assumed to be close to the maximum transport velocity (Tmax) as
apparent Michaelis half-saturation constant for glucose transport
(Kt below 1.5 mM with reversible Michaelis–Menten kinetics) is
much lower than plasma glucose in this study (Duarte and Gruetter
2012a). Thus, Tmax was estimated according to eqn 4 and then used
to determine the ratio of Tmax/CMRglc for the different brain
structures:
Tmax ¼ K1;FDG  K1;glcK1;FDG 
Gp
1:04 g/mL
ð4Þ
A tissue density of 1.04 g/mL was assumed. The transport
coefﬁcient for FDG versus glucose was K1;FDGK1;glc = 1.66, which is the
average of the two available literature values for normoglycemic
rats: 1.65 at Gp = 9 mM (Fuglsang et al. 1986) and 1.67 at
Gp = 9.9 mM (Crane et al. 1983).
Data from MRSI were processed with home-written MATLAB
(TheMathWorks,Natick,MA,USA) codes as previously detailed (Alf
et al. 2012) and metabolite quantiﬁcation was done with LCModel
version 6.2-0X (Stephen Provencher Inc., Oakville, Ontario, Canada).
MRSI data sets were processed independently from PET images
(without coregistration) and regions of interest were manually
delineated based on anatomical T2-weighted MRI scans. As for PET
data, a 4.2% fractional blood volume in the brain was taken into
account. The glucose distribution volume Vd was ﬁxed at 0.77 mL/g,
consistent with the brain water content for absolute quantiﬁcation
(Lund-Andersen 1979). Metabolite maps of glucose were generated,
interpolated and superimposed on anatomic images (Fig. 1b).
The reversible Michaelis–Menten model of steady-state glucose
kinetics was then applied using eqn 5 (Gruetter et al. 1998), which
is valid under the range of plasma glucose analysed in this study
(Duarte et al. 2009b).
Gbrain ¼ Vd
Tmax
CMRglc
 1
 
Gp  Kt
Tmax
CMRglc
þ 1 ð5Þ
As the apparent half-saturation constant for glucose transport at
the blood–brain barrier is the poorest estimated parameter when
studying glucose dynamics in vivo (Duarte et al. 2009b), we ﬁrst
proceeded with a ﬁt of eqn 5 to all measured voxels simultaneously.
The resulting value for Kt was then used to perform data ﬁtting on
all individual voxels. Finally, glucose maps were coregistered to
create a map of Tmax/CMRglc for region-of-interest analysis,
analogous to the determination of the ratio from FDG-PET data.
Results from PET and MRSI were then combined to obtain a
new, experimental value of the LC as follows. Tmax/CMRglc
(a) (b)
Fig. 1 (a) A typical image of 18F-ﬂuoro-
deoxyglucose (FDG) uptake after 45 min. ROIs
from which time activity curves (TACs) were
derived are shown. Plasma glucose in this animal
was 10.7 mmol/L. Delineated brain areas are as
follows: SS-Ctx, somatosenory cortex; RS-Ctx,
retrosplenial cortex; HIP, hippocampus; THA,
thalamus. (b) Typical maps of glucose superim-
posed on an anatomic MRI scan (top). In the map
acquired after glucose infusion, Gp was between
16.5 and 17.8 mmol/L.
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determined with either method must be the same, with the LC in the
equation for PET being the only parameter free to choose.
LCisoﬂurane can therefore be determined through eqn 6:
Tmax;PETLCisoflurane
KFDGGp
Tmax;MRSI
CMRglc
¼ 1 ð6Þ
which can be written as follows:
LCisoflurane ¼ Tmax;MRSI
CMRglc
 K1;FDG
K1;glc
 k3
k2 þ k3 ð7Þ
After determining LCisoﬂurane, correct values of CMRglc were
calculated.
Error propagation was taken into account throughout all layers of
analysis. All data are shown with associated SD.
Results
PET kinetic modelling
Of the six rats included in the FDG-PET study, ﬁve had a Gp
of 10.8  0.5 mmol/L. One rat had a lower initial Gp
(7.1 mmol/L) that changed substantially during the scan and
was therefore excluded from the analysis. Kinetic model
ﬁtting using the two-tissue compartment model as imple-
mented in PMOD could be performed with an excellent data
ﬁt in all ﬁve data sets (example shown in Fig. 2a), with and
without a rate constant for dephosphorylation, k4, included in
the model. Results for the rate constants, the CMRglc
(determined with LC = 0.7) and Tmax are shown in Table 2.
Tmax revealed signiﬁcant regional variations, with the value
in retrosplenial cortex being signiﬁcantly higher than that in
hippocampus (with model including k4: 149  23 vs.
105  16 lmol/min/100 g, model excluding k4: 152  20
vs. 108  13; n = 5, p < 0.05, two-tailed paired-sample
t-test). CMRglc was relatively uniform with differences below
10% across different brain regions when calculated with an
LC of 0.7 in all regions. Tmax/CMRglc was calculated and is
shown in Table 3. The rate constant for dephosphorylation,
k4, was found to be close to zero, with its SD being larger
than its absolute value. Omitting k4 from the analysis did not
lead to signiﬁcantly different results.
Parameters from MRSI
Physiologic parameters of the animals used for MRSI are
summarized in Table 4. Plasma lactate increased when Gp
was increased via glucose infusion. This was also visible in
brain lactate maps (not shown). As in previous reports on
single volume MRS data (Duarte et al. 2009a; Duarte and
Gruetter 2012a), we did not observe major changes in
metabolites other than glucose and lactate. A few maps had
to be discarded because of issues with poor signal-to-noise
ratio or lipid contamination. In the remaining data sets,
(a) (b)
(c) (d) (e)
Fig. 2 (a) Typical hippocampal time activity curve (TAC, circles
correspond to the centres of reconstructed time frames) and input
function from a positron emission tomography PET experiment with
model ﬁt. The y-axis shows total 18F activity from 18F-ﬂuoro-deoxyglucose
(FDG) and FDG-6-phosphate (FDG6P). The black lines represent
the intracellular pools of free FDG and FDG6P simulated with
the software PMOD. These plus the plasma FDG (red line) within
brain capillaries result in the total PET signal (shown in blue). (b)
Glucose maps were coregistered for single-voxel regression analysis.
A voxel size is illustrated in the lower right corner of the map in front.
(c) Data recorded from the voxel highlighted in ﬁgure part b
from all animals. Linear regression constrained by Kt = 2.1 mmol/L
on data from an example voxel, highlighted in (b) in white. (d)
Quality of regression as indicated by R2 for all voxels included in
the map. (e) Regression results for Tmax/CMRglc visualized in a heat
map.
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single-voxel signal to noise ratio was 5–24 and Cramer-Rao
lower bounds of glucose concentration were between 6% and
29%, as estimated by LCModel (Stephen Provencher Inc).
A total of 13 maps of glucose concentration at different Gp
were used to determine a general value for Kt and then to
generate the brain map of Tmax/CMRglc in the voxel-wise
regression analysis, as described in the methods section. In
agreement with our previous dynamic 1H MRS study (Duarte
and Gruetter 2012a; that revealed Kt 1.5 mmol/L (95% CI: 0;
17)), an overall Kt of 2.1  0.6 mmol/L (95% CI: 1.1; 3.1)
along with an overall Tmax/CMRglc of 2.0  0.1 (95% CI:
1.9; 2.1) resulted in the best ﬁt (R2 = 0.46) of the reversible
Michaelis–Mentenmodel.Using this value forKt, highR
2were
obtained for most ﬁts of individual voxel data (Fig. 2b–d).
Voxels with ﬁts resulting in R2 < 0.5 were all situated in either
cornersof themapor itsbottomrow.Theregionaldistributionof
Tmax/CMRglc is shown inFig. 2e.Tmax/CMRglc ranged from1.8
in voxels of the hippocampus or thalamus to 2.5 in the
retrosplenial cortex.Mean values for the brain areas in themap,
i.e. retrosplenial cortex, somatosensory cortex, hippocampus
and thalamus, were then computedwithout including voxels of
the sinus and the corners (Table 3). Gbrain for Gp = 10.8
Table 2 Results from two-tissue compartment modelling of FDG-PET data, including or excluding k4 in the model. Tmax was calculated as
described in eqn 4. The values of CMRglc presented in this table were calculated with LC = 0.7 as an initial assumption that would only be correct in
awake animals. Brain areas are as follows: SS-Ctx, somatosenory cortex; RS-Ctx, retrosplenial cortex; HIP, hippocampus; THA, thalamus
K1
(mL/min/cm3) k2 (min
1) k3 (min
1) k4 (min
1)
KFDG
(mL/min/cm3)
CMRglc
(lmol/min/100 g)
Tmax
(lmol/min/100 g)
Model including k4
RS-CTX 0.24  0.03 0.43  0.04 0.04  0.01 0.003  0.008 0.020  0.002 29.3  3.4 149  23
SS-CTX 0.21  0.03 0.42  0.07 0.05  0.01 0.004  0.004 0.021  0.002 30.8  3.4 128  19
HIP 0.17  0.02 0.34  0.09 0.05  0.02 0.005  0.009 0.023  0.005 34.0  6.0 105  16
THA 0.20  0.04 0.40  0.08 0.05  0.01 0.005  0.007 0.021  0.003 31.6  4.7 123  27
Model excluding k4
RS-CTX 0.24  0.03 0.44  0.05 0.04  0.01 0.019  0.003 28.1  4.1 152  20
SS-CTX 0.21  0.02 0.43  0.03 0.04  0.01 0.020  0.002 29.0  3.1 132  10
HIP 0.17  0.02 0.34  0.05 0.05  0.01 0.021  0.002 31.3  2.2 108  13
THA 0.20  0.03 0.40  0.05 0.04  0.01 0.020  0.001 29.7  2.8 123  21
Table 3 Summary of glucose transport and consumption results obtained with the combined PET-MRSI analysis. Tissue glucose concentration
Gbrain was calculated at Gp = 10.8 mmol/L (average for animals in the PET study) with two different approaches. Results are shown for models
including and excluding k4 as in the original publication of the two-tissue compartment model (Sokoloff et al. 1977). Brain areas are as follows:
SS-CTX, somatosenory cortex; RS-CTX, retrosplenial cortex; HIP, hippocampus; THA, thalamus
RS-CTX SS-CTX HIP THA
Tmax/CMRglc (from MRS) 2.5  0.1 2.2  0.1 2.0  0.1 2.0  0.1
Gbrain (lmol/g, from MRS) 3.1  0.1 2.6  0.1 2.2  0.1 2.1  0.1
Model with k4 Tmax/CMRglc (from PET) 5.1  1.0 4.2  0.4 3.1  0.3 3.9  0.4
LCisoﬂurane 0.33  0.07 0.37  0.04 0.44  0.05 0.35  0.04
CMRglc (lmol/min/100 g) 62  14 58  12 54  11 63  12
Model without k4 Tmax/CMRglc (from PET) 5.4  0.6 4.6  0.6 3.4  0.4 4.2  0.6
LCisoﬂurane 0.32  0.03 0.33  0.04 0.40  0.04 0.33  0.05
CMRglc (lmol/min/100 g) 62  10 61  7 55  4 63  6
Table 4 Average physiologic parameters during baseline and hyperglycaemia clamp in MRSI. PaO2 was relatively high because of the mixture of
30% pure oxygen in air. Baseline plasma glucose ranged from 7.4 to 13.8 mmol/L, under glucose clamp conditions from 16.5 to 22.6 mmol/L
Arterial pH PaCO2 (mm Hg) PaO2 (mm Hg) O2 saturation Plasma lactate (mM)
Baselinea 7.36  0.04 43.0  2.0 245  42 99.8  0.1% 2.2  0.6
Glucose clamp 7.31  0.07 38.8  3.7 280  75 99.9  0.1% 4.8  0.9
aThese parameters were not measured during PET experiments as these lasted only 60 min and no changes were expected.
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mmol/L (PET study average) was then estimated using eqn 5
and the parameters for the different structures. Values were
between 2.1 and 3.1 lmol/g (Table 3).
Estimation of LCisoflurane
Compared to MRSI, the ratio Tmax/CMRglc was overesti-
mated by PET with a factor around 2, when based on the
initially assumed LC of 0.7. As a consequence, the actual
LCisoﬂurane must be about half of the initial assumption.
Region-speciﬁc values for the LC were derived using eqn 6
(Table 3). The highest LCisoﬂurane of 0.44  0.05 (k4
included in kinetic model, 0.40 when k4 was excluded)
was obtained in hippocampus, which was signiﬁcantly higher
than the LCisoﬂurane obtained in the other regions (p < 0.05,
one-way ANOVA), with the other ones being relatively similar
(0.33  0.07, 0.37  0.04 and 0.35  0.04 for retrosplenial
and somatosensory cortex and thalamus respectively; with k4
excluded from the model: 0.32  0.03, 0.33  0.04,
0.33  0.05).
When computed with the LCisoﬂurane determined in this
study, CMRglc was between 54 and 63 lmol/min/100 g in
hippocampus and thalamus, respectively, with no major
dependence on whether k4 was included in PET kinetic
modelling or not (Table 3).
Discussion
The combination of PET and 1H MRSI was used to determine
region-speciﬁc LC values in the rat brain under isoﬂurane
anaesthesia. LCisoﬂurane in the four analysed brain areas was
lower than those previously reported for both anaesthetized
and awake animals (Table 1), and yielded CMRglc values that
are close to those determined by autoradiography (Hansen
et al. 1989; Archer et al. 1990), as well as by LC-independent
MRS (Du et al. 2012; Duarte and Gruetter 2012a).
The present approach to estimate LC relies on knowing the
maximum glucose transport rate (Tmax) determined by FDG-
PET and on its ratio to glucose consumption (Tmax/CMRglc)
measured by 1H MRSI. Both Tmax and Tmax/CMRglc reported
in this study were in good agreement with previous
determinations in the rat brain under isoﬂurane anaesthesia
by dynamic measurement of brain and plasma glucose
concentrations (Du et al. 2012; Duarte and Gruetter 2012a).
To allow estimating LC, non-measured parameters were
taken from the literature. Since they apply to calculations in
both MRSI and PET data, such assumptions are devoid of
substantial effects on the calculated LC values. Namely, the
volume of distribution of glucose in the brain was assumed to
be equal to brain water content (Lund-Andersen 1979) and a
value for fractional blood volume was taken from synchro-
tron radiation CT data (Adam et al. 2003). It is also implicit
in the present analysis that glucose homeostasis is identical in
MRSI and PET experiments, i.e. that glucose transport and
consumption are invariable within the range of plasma
glucose concentrations of this study, and are not substantially
affected by the presence of FDG in tracer amounts. Indeed,
variations in glucose transport and phosphorylation rates
were negligible in the mouse brain within the glycaemia
range of the present experiments (Alf et al. 2013b). In
contrast, assumptions that may affect either MRSI or PET
data independently are discussed below.
The present FDG-PET data were analysed with two model
variants assuming reversible and irreversible phosphoryla-
tion. They yielded similar results (within the reported SD).
The difference in LCisoﬂurane was at most 12% (somatosen-
sory cortex). An earlier study in conscious rats using 14C-DG
found that the inclusion of k4 in the CMRglc calculation may
lead to a 44% overestimation of CMRglc (Schmidt et al.
1995). Such overestimation of CMRglc was not observed in
our study under isoﬂurane. The contrast between the two
studies may arise from the effects of isoﬂurane in the
regulation of brain glucose homeostasis, which are not
present in awake animals, as well as from the employment of
different glucose analogs (14C-DG vs. FDG).
Estimation of Kt and Tmax/CMRglc from MRSI data
The apparent half-saturation constant for glucose transport
into brain parenchyma (Kt) was 2.1  0.6 mmol/L, in
agreement with our earlier work using the reversible
Michaelis–Menten kinetics for glucose carriers (Duarte and
Gruetter 2012a). This is, however, a parameter that varies
considerably in the literature as it depends on the kinetic
model attributed to the glucose carrier at the blood–brain
barrier. The employment of the reversible Michaelis–Menten
kinetics to describe glucose transport at the blood–brain
barrier resulted in a Kt lower than that determined using the
standard Michaelis–Menten model in earlier studies (com-
parison in Duarte and Gruetter 2012b). In this study, Kt was
determined with data pooled from all analysed voxels to
achieve higher precision and then constrained for the
determination of Tmax/CMRglc in a voxel-wise manner. With
Kt ﬁxed at 2.1 mmol/L for all brain regions, we measured
higher Tmax/CMRglc in cortical tissue, especially in the
retrosplenial cortex (Fig. 2e), which may be partly owing to
pial vessels contributing to a higher fractional blood volume
in this region, compared to the underlying tissue (Chugh
et al. 2009). Although voxels of the sinus were not included
in the analysis, partial volume effects causing signal spill
over would lead to overestimation of Tmax/CMRglc and thus
LCisoﬂurane. This artefact may be considered negligible as,
slightly higher Tmax/CMRglc was indeed found in the rat
cortex (Lei et al. 2010) compared to the hippocampus
(Duarte et al. 2009a), and CMRglc is generally lower in the
cortex than hippocampus (Table 1).
Although the physiological variation of Kt within the
analysed brain regions cannot be excluded, simulations of the
effect of Kt on Tmax/CMRglc and thus on LC estimation
(Fig. 3a) indicated that variations of 50% in the value of Kt
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resulted in changes in the LCisoﬂurane (and Tmax/CMRglc)
smaller than 6%. An increase in LCisoﬂurane of 11% was
found when doubling the value of Kt to 4.2 mmol/L, which is
higher than any estimation with the reversible Michaelis–
Menten model of glucose carriers across different species
(Duarte and Gruetter 2012b).
Rate constants and Tmax from FDG-PET data
Kt in the rat brain in vivo determined from MRSI data was
much lower than plasma glucose in the animals used for PET
experiments. As such, we assumed that glucose transport
(Tglc) estimated from K1 is close to Tmax. The values for Tmax
obtained in this manner (105–152 lmol/min/100 g) were
close to the Tmax of 137 lmol/min/100 g obtained for the rat
brain (cortex+hippocampus) in a 1H MRS study under
similar anaesthesia protocol (Duarte and Gruetter 2012a) and
in line with LC-independent measurements of Tmax under
different experimental conditions, ranging from 91 to
135 lmol/min/100 g (Duarte et al. 2011; Du et al. 2012).
As this assumption may result in underestimating Tmax from
PET data, we simulated the effect of Tmax on LC
isoﬂurane
(Fig. 3b), which indicated that a 20% increase in Tmax
estimated from PET experiments (relative to values on
Table 2) would result in 17–18% decrease in LCisoﬂurane in
the four regions of interest analysed.
Furthermore, sinceK1 for glucose (K1,glc)was notmeasured,
the estimation of Tmax from PET data relied on previous
determinations of the coefﬁcient of transport rate constants
K1,FDG/K1,glc that was 1.66 for adult rats at a glycaemia of
9–10 mM (Crane et al. 1983; Fuglsang et al. 1986), not
substantially different from the present FDG-PET study
(10.8  0.5 mmol/L). The value of K1,FDG/K1,glc used in this
study seems to be appropriate as it draws upon two indepen-
dently achieved results from the literature that differ < 2%
from each other, and also K1 remains unchanged relative to
awake rats in vivo (Mizuma et al. 2010). Nevertheless, care
should be taken when extrapolating the present data to other
experimental conditions where K1,FDG/K1,glc may vary, as it
was shown for newborn rats (increase of~16%; Fuglsang et al.
1986). In humans, K1,FDG/K1,glc was 1.48 and did not change
under hypo- or hyperglycaemia (Hasselbalch et al. 1996).
Simulations with the data from our study indicated that
variations of K1,FDG/K1,glc have a proportional effect on the
estimated LC. For the sake of example, a variation of 10% in
K1,FDG/K1,glc in the somatosensory cortex (between 1.49 and
1.83) resulted in LC to vary between 0.33 and 0.41 (model
including or not k4), which is within the associated variance
(Fig. 3c).
Based on previous work measuring brain glucose concen-
trations in a vast range of experimental conditions with both
microdialysis and MRS methods (reviewed in Barros et al.
2007; Duarte and Gruetter 2012b), we consider that Gbrain as
assessed with MRSI reﬂects its true value in the present
work. Thus, with the measured values of Gbrain by MRSI and
the calculated CMRglc, one can estimate a coefﬁcient of
phosphorylation rate constants k3;FDGk3;glc , as deﬁned by Crane
et al. (1983), using an expression similar to eqn 1:
CMRglc ¼ k3;FDG k3;glck3;FDG Gbrain  1:04 g/mL ð8Þ
This analysis resulted in k3;FDGk3;glc ranging from 0.17 to 0.23
across the four regions of interest. This is lower than the
coefﬁcient obtained in other studies in rats with FDG
(0.50–0.55; Crane et al. 1983; Fuglsang et al. 1986) or
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Fig. 3 (a) Simulation of the effect of Kt on the determination of
Tmax/CMRglc from magnetic resonance spectroscopic imaging (MRSI)
data and, consequently, on the estimation of LCisoﬂurane, using
18F-ﬂuoro-deoxyglucose (FDG)-PET rate constants averaged across
the four brain regions (model including k4). The experimentally
determined Kt = 2.1 mM is represented by the dashed line. (b) Effect
of Tmax estimated from FDG-PET data on LC
isoﬂurane. The shaded area
represents the values of Tmax obtained experimentally in this study for
the regions of interest. (c) Effect of varying K1,FDG/K1,glc on the
determination of Tmax/CMRglc and/or LC
isoﬂurane. The dashed vertical
line represents the value assumed for LC estimation. Regions of
interest are as follows: RS-CTX, retrosplenial cortex; SS-CTX, soma-
tosenory cortex; HIP, hippocampus; THA, thalamus. On panels (b) and
(c), right and left graphs are simulations with FDG-PET rate constants
in models with and without k4, respectively.
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deoxyglucose (0.37; Cunningham and Cremer 1981), in
agreement with the lower LC values determined in this study.
In this context, it should be noted that isoﬂurane substantially
decreases k3 itself relative to the awake state in the mouse
brain (Mizuma et al. 2010).
Despite the mentioned shortcomings, our approach repre-
sents a solid basis compared to strategies that rely on
additional assumptions included in operational deﬁnitions
and/or hexokinase afﬁnities or single rate constants from the
literature. We therefore argue that the explanation of why our
LCisoﬂurane is lower than in previous reports is likely to be
found in these additional assumptions.
Physiological effects of isoflurane
In this study, we report LC values that may not be applicable to
experiments under anaesthesia protocols other than the widely
used isoﬂurane. Isoﬂurane inﬂuences brain and peripheral
metabolism, particularly increasing brain and plasma lactate
and glucose levels (Saha et al. 2005; Duarte and Gruetter
2012a; Boretius et al. 2013). These did not vary during the
time frame of the present PET andMRSImeasurements. Aswe
use a glycaemic clamp to control for plasma glucose after the
ﬁrst half of theMRSI session, we do not expect the inﬂuence of
isoﬂurane on plasma glucose to be of importance. Although
CMRglc has been found to be similar in the rat brain under
a-chloralose and isoﬂurane anaesthesia (Duarte et al. 2011;
Duarte and Gruetter 2012a), that are characterized by distinct
plasma and brain lactate levels, inﬂuence of lactate on other
brain metabolic processes would beneﬁt from further research.
Another effect of isoﬂurane anaesthesia is that it makesCMRglc
more uniform across the brain than it is in the awake state, as
discussed previously (Toyama et al. 2004) and as visible in our
data. This does not prohibit its use in most experimental
protocols, as long as it is kept in mind. However, in addition to
the above-mentioned effects, it further precludes our results
from being transferable to experiments with other types of
anaesthesia or in the awake state.
Experimental limitations
In MRSI, slight differences were observed between the left
and right hemispheres. These are probably owing to partial
volume effects, a generalized problem in MR imaging and
particularly in MRSI (discussed in Alf et al. 2012). The real
voxel size of the glucose maps (1.4 lL) is relatively large
compared to the size of brain structures, resulting in voxels
that are weighted averages of spectra containing different
brain structures. This kind of image artefacts could be
reduced by developing MRSI methods with higher spatial
resolution, but with loss in the signal-to-noise ratio within the
same acquisition time, which is important when quantifying
low concentrated metabolites like glucose.
It should also be noted that distinct animals were used for
the MRSI and PET experiments, although strain and housing
conditions were identical, thus minimizing metabolic and
physiological variations. The rats were 7 and 8 weeks old for
PET and MRSI, respectively, and this age difference has not
been demonstrated to have an effect on brain energy
metabolism, to our knowledge. Nevertheless, more reliable
estimations of LC can be envisaged by employment of newly
developed instruments that combine both imaging methods
(Torigian et al. 2013) for simultaneous FDG-PET and
dynamic 13C MRS with infusion of 13C-enriched glucose
as the latter provides independent measures of Tmax, CMRglc
and Kt (Duarte et al. 2011).
Conclusion
This study reports region-speciﬁc values for the FDG LC in
the rat brain under isoﬂurane anaesthesia that were
estimated with as few assumptions as possible. Our results
suggest that the ratio of the afﬁnities of hexokinase for
glucose and FDG may be decreased under isoﬂurane
compared to the awake state or, possibly, under other
anaesthetic agents, which could explain why previous
attempts to determine the LC have not resulted in its
correct assessment. These region-speciﬁc LC values may
contribute to a better comparability of quantitative assess-
ments of cerebral energy metabolism using FDG-PET.
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